Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bvax in Newly Diagnosed Glioblastoma
NCT07422896Phase 1Not yet recruiting
- Start
- Dec 2026
- Primary completion
- Sep 2028
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Bvax in glioblastoma (GBM). Primary endpoint: Incidence of adverse events at 90 days. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Bvax
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07422896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07422896.